PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Progestational Hormones”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1988

[New progestational hormones].

The pharmacology and the application in oral hormonal contraceptives of four new progestogens--gestodene, desogestrel, norgestimate, and dienogest--are described in a survey. Although derived from 19-norethisterone these progestogens exhibit in clinical dosages no androgenic effects. Both in animal and in human tests gestodene possesses the highest progestogenic potency followed by levonorgestrel, desogestrel, norgestimate, and dienogest. The monophasic preparations with the new progestogens (femovan--gestodene, marvelon--desogestrel, cilest--norgestimate, certostat--dienogest) are safe contraceptives and the incidence of bleeding disturbancies amount to about 5%. After administration of these monophasic contraceptives the concentration of SHBG in serum increases and as a result of this the level of free testosterone decreases. Further a favourable effect on lipid metabolism is observed. In spite of a different progestogen content these combination pills are almost without influence on biochemical parameters and carbohydrate metabolism.

Contraceptives, Oral, Hormonal↗
PubMed1990

[The characteristics of triphasic estrogen-progesterone contraceptives and their theoretical indications].

In the long history of oral contraception, unfortunate events have been associated with the use of oestrogens and progestogens. The discovery of new progestational hormones with weak androgenic activity but powerful progestational action has led to the combination of very low doses of ethinyloestradiol with low doses of progestational hormones which progressively increase in three successive stages. The products thus show excellent safety, accompanied by a minimum of incidents, and are extremely reliable contraceptives.

Blood Coagulation↗
PubMed1977

The relationship between congenital defects and the use of exogenous progestional "contraceptive" hormones during pregnancy: a 20-year review.

This review of 20 years of medical literature on the occurrence of congenital defects among offspring of women who ingested "progestational" or contraceptive hormones during pregnancy emphasizes the need for additional studies with carefully selected control groups. Other problems encountered in interpreting the existing literature, including the use of imprecise definitions, confusing nomenclature and inadequate clinical information, are also discussed.

Abnormalities, Drug-Induced↗
PubMed1978

[Effect of long-term progestational treatment on the course of endometrial adenocarcinoma].

Author studied the effect of prolonged--6-8 month--treatment with Hormofort on the cells of adenocarcinoma of the endometrium. Light- and electronmicroscopic studies show, that after the treatment with progestative hormones cells of the adenocarcinoma seems significantly regrediate and simultaneously clinical remission can be observed. These data suggest, that progestative-norsteroids seems to elicit "cytostatic" effect on the endometrical tumour cells.

Adenocarcinoma↗